In our prior study, we show that reactive oxygen species (ROS) generation via CoCl2 or IL-6 treatment enhances this TET1 pathway and ROS neutralization via catalase represses this pathway [32], potentially explaining the inflammatory hallmark of clinical obesity as a risk factor for TNBC [12]. The gene discussed is TET1; the disease is obesity due to melanocortin 4 receptor deficiency.